Healthcare
Home » Rare Inflammatory Disease Treatment Market

Rare Inflammatory Disease Treatment Market

Rare Inflammatory Disease Treatment Market By Indication (Ulcerative Colitis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Other) By Drug Class (Biologics, Organic Compounds) By Mode of Administration (Injectables, Oral, Others) By Distribution Channel (Hospital Pharmacies, and Retail Pharmacies) Growth, Future Prospects & Competitive Analysis, 2016 – 2030
Report Book

Published Date: April 2023
Category: Healthcare
Report ID: 60951
Report Format: PDF
No of Pages: 190

Rating: Credence Reports

Key Highlights of the report

How are the major segments performing in the Rare Inflammatory Disease Treatment market?

  • In 2022, the Ulcerative Colitis segment accounted for the largest market share owing to the growing prevalence rate compared to other rare inflammatory diseases.
  • In 2022, the Biologics segment was anticipated to hold a prominent share in the global Rare Inflammatory Disease Treatment market as several R&D activities on bio9logic therapies exist.
  • In 2022, the Injectables segment accounted for the largest market share owing to increased effectiveness and dosage deliverable through injections.
  • In 2022, the Hospital Pharmacies segment was anticipated to hold a prominent share in the global Rare Inflammatory Disease Treatment market as patients prefer purchasing medicines from hospitals that they are receiving the treatment.

What is the Market Size of Rare Inflammatory Disease Treatment regarding value?

The global Rare Inflammatory Disease Treatment market is anticipated to grow at a substantial CAGR of 4.80% in the upcoming years. The global Rare Inflammatory Disease Treatment industry was estimated to be worth USD 13548.6 billion in 2022 and was expected to be worth USD 188.11 billion by 2030.

Rare Inflammatory Disease Treatment Market

Which region dominated the Rare Inflammatory Disease Treatment market?

In 2022, the North American region was anticipated to hold a major share of the global Rare Inflammatory Disease Treatment market. One of the main growth drivers is an advanced healthcare system and numerous reimbursement programs designed to make it easier for people with rare illnesses to access treatment. Rare diseases affect more than 30 million people in America.

How US Market is Performing in the Rare Inflammatory Disease Treatment market?

In 2022, the U.S. was anticipated to hold a prominent share in the North American region’s global Rare Inflammatory Disease Treatment market. Juvenile rheumatoid arthritis is one of the most frequently diagnosed pediatric arthritic diseases in the United States, and approximately 6,200 Americans are affected by diseases each year, including Polycythemia Vera. Hospitals, retail, and online pharmacies are just a few distribution channels where the demand for medications to treat rare inflammatory diseases has increased. As a result, the United States is anticipated to hold the largest market share for treating rare inflammatory diseases.

How is the economy impacting the global Rare Inflammatory Disease Treatment growth?

The global cancellation of elective procedures, including treatment and diagnostic procedures, caused by the COVID-19 pandemic significantly impacted the market for treating rare diseases. Due to the COVID-19 pandemic’s suspension of research projects and clinical trials for rare and genetic diseases, clinicians, researchers, and scientists who work on these diseases faced additional challenges due to the pandemic. However, since the restrictions were removed, the market has rebounded. Throughout the forecast period, the market is anticipated to grow steadily.

What is the competitive environment of the Rare Inflammatory Disease Treatment market?

The top manufacturers are speeding up drug development in the global market for treating rare inflammatory diseases. The potential of new drug classes to treat uncommon inflammatory diseases presents market players with a lucrative opportunity. PRX-102 (pegunigalsidasealfa), for treating adult Fabry disease patients, was resubmitted to the US Food and Drug Administration (FDA) in November 2022 by ProtalixBiotherapeutics Inc. and Chiesi Global Rare Diseases. In addition, Alexion Pharmaceuticals, Inc. was purchased by AstraZeneca in July 2021 for USD 13.3 billion. The company’s product portfolio for rare diseases is strengthened by this acquisition, which also presents the company with a significant opportunity for growth.

Executive Summary

What are the key trends in the Rare Inflammatory Disease Treatment market?

  • Numerous initiatives are being developed by various governments worldwide for the treatment of rare diseases. For instance, the National Policy for Rare Diseases 2021 of the Indian government sought to reduce the incidence and prevalence of rare diseases based on a comprehensive and integrated preventive strategy. This includes raising awareness, premarital, postmarital, pre-conception, and post-conception screening and counseling programs to reduce the risk of having children with rare diseases. Within the constraints of limited resources and competing healthcare priorities, this also enables patients with rare diseases amenable to a single treatment or relatively inexpensive therapy to access affordable healthcare.
  • The Center for Drug Evaluation and Research (CDER) also approved about 26 new orphan drugs in 2021 to manage rare diseases.

How is the Increasing Prevalence of Various Diseases Affecting the Growth of the Rare Inflammatory Disease Treatment Market?

Autoimmune and inflammatory diseases are becoming more commonplace very quickly. Around 100 million people worldwide have psoriasis, and 1.3% and 34.7% develop chronic and inflammatory arthritis, according to the World Health Organization. The prevalence of inflammatory bowel diseases like ulcerative colitis and Crohn’s disease is rising alarmingly in previously unaffected regions worldwide. As a result, doctors are developing several drug candidates to treat some of the most severe rare inflammatory diseases.

Which are the key investments by the Rare Inflammatory Disease Treatment market players?

Governments and companies in the market are taking initiatives to launch new products and invest in the R&D of new treatments and drugs that are more effective. In Oct 2022, the US Food and Drug Administration, ten pharmaceutical companies, five non-profit organizations, and the National Institutes of Health collaborated to hasten the development of gene therapies for the 30 million Americans who suffer from rare diseases.

Some major players in the Rare Inflammatory Disease Treatment market are Pfizer Inc, Bausch Health Companies Inc, Novartis AG, Allergan Plc, Abbott, Regeneron Pharmaceuticals, Inc., Abbvie, Inc., Mallinckrodt, Celtaxsys, and CSL

What are the Major Driving Factors for the Rare Inflammatory Disease Treatment Market?

Rising R&D activities for novel therapeutics and drugs, an increase in the number of new drug launches, an increase in the number of rare disease cases and initiatives in favor of vaccinations, as well as an increase in the number of new drug launches and supportive government policies, are all actively influencing the growth of the market under study. The US FDA’s Center for Drug Evaluation and Research (CDER) introduced the Accelerating Rare Disease Cures (ARC) Program in May 2022 as a new initiative to hasten the development of novel therapies for rare diseases. Such developments are anticipated to fuel the market’s growth during the forecast period. The market for treating rare diseases is anticipated to grow as the need for such treatments becomes more widespread.​ A strong product pipeline and upcoming launches are also anticipated to support market expansion. According to Pharmaceutical Research and Manufacturers of America, in 2021, there were approximately 791 potential orphan drug candidates undergoing clinical trials for the treatment of rare diseases. Clinical orphan drugs were used to treat 192 genetic disorders, 56 neurological disorders, 54 blood disorders, 51 autoimmune diseases, and 36 infectious diseases, out of which 168 were for rare cancers and 120 for rare blood cancers.

What are the Major Risks for the Rare Inflammatory Disease Treatment Market?

It is challenging for researchers to define and comprehend these uncommon diseases because there isn’t a single comprehensive database. The signs and symptoms can differ from person to person, as with many diseases. It can be challenging for doctors to diagnose accurately when there aren’t many people to observe and study. The high cost of research and development for pipeline candidates used to treat rare diseases, which also contributes to the increase in drug prices, could impede the market growth.

Which is the key application in the Rare Inflammatory Disease Treatment market?

The ulcerative colitis e segment is expected to hold a prominent share in the global Rare Inflammatory Disease Treatment market during the forecast period. Manufacturers will be influenced to expand their manufacturing capacities for cutting-edge drugs and therapies in the future due to the significant cost savings associated with ulcerative colitis treatments. The development of cutting-edge ulcerative colitis treatments has been aided by technological developments and an increase in the number of patients who suffer from the condition. The market demand for treatments for rare inflammatory diseases has increased due to new therapeutics, the need for enhancing drugs, and improvements in managing ulcerative colitis.

How is the Rare Inflammatory Disease Treatment market performing in regions?

Asia Pacific market is anticipated to witness the fastest growth in the global Rare Inflammatory Disease Treatment market during the forecast period. Growing government programs aimed at helping people with orphan diseases are responsible for the region’s growth. For instance, in July 2022, the Indian government gave national and state governments instructions to ensure that health policies created for treating patients with orphan diseases were effectively implemented. This policy allows producers to earn money by providing the government with top-notch orphan drugs.

What is the regulatory landscape for the Rare Inflammatory Disease Treatment market?

Turning scientific advancements into brand-new drug treatments for rare, serious, and life-threatening disorders is incredibly difficult. All stakeholders who support the need for flexibility in the regulatory review process for novel therapeutics to treat rare diseases are aware of this difficulty. The development of the Accelerated Approval (AA) pathway in the US is the best example of this flexibility. The AA pathway has been extensively used to develop medications for treating cancer and other infectious diseases, two conditions with high unmet medical needs. The FDA, EMA, and other regulatory bodies, among others, are involved in approving the treatment process and the drugs used for different treatments.

What are the major players planning for the future of the Rare Inflammatory Disease Treatment market?

To address the unmet needs in treating rare diseases, a multidisciplinary approach with creative proposals for developing novel SMA drugs is anticipated to fuel industry growth. For instance, a set of policy recommendations to address unmet medical needs in rare diseases were unveiled in June 2021 by the European expert group on orphan drug incentives. This policy proposal calls for updating the EMA’s pharmaceutical strategy and orphan drug regulations to encourage R&D spending on orphan drugs. In addition, fundamental studies on patient access, difficulties in clinical development, and regulatory approval procedures are significant issues emphasized in policy proposals. Such encouraging government programs might aid the industry’s growth over the forecast period.

REPORT ATTRIBUTE DETAILS
Rare Inflammatory Disease Treatment Market by Value Yes
Rare Inflammatory Disease Treatment Market, Tornado Analysis Yes
Rare Inflammatory Disease Treatment Market, STAR Analysis Yes
Rare Inflammatory Disease Treatment Market, SRC Analysis Yes
Rare Inflammatory Disease Treatment Market Pricing Analysis Yes (On Demand)
Rare Inflammatory Disease Treatment Market Segment Analysis By Indication (Ulcerative Colitis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Other)

By Drug Class (Biologics, Organic Compounds)

By Mode of Administration (Injectables, Oral, Others)

By Distribution Channel (Hospital Pharmacies, and Retail Pharmacies)

Rare Inflammatory Disease Treatment Market, Regional Analysis North America (US and Canada)

Europe (Germany, UK, France, Italy, Spain, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, South East Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East and Africa (GCC Countries, South Africa, and Rest of Middle East and Africa)

Rare Inflammatory Disease Treatment Market Key Companies Pfizer Inc, Bausch Health Companies Inc, Novartis AG, Allergan Plc, Abbott, Regeneron Pharmaceuticals, Inc., Abbvie, Inc., Mallinckrodt, Celtaxsys, and CSL
Rare Inflammatory Disease Treatment Market Competitive Landscape Market Share Analysis

Competitive Benchmarking

Key Players Market Positioning

Geographical Presence Analysis

Major Strategies Adopted

Segmentation of Global Rare Inflammatory Disease Treatment Market-

Global Rare Inflammatory Disease Treatment Market – By Indication

  • Ulcerative Colitis
  • Juvenile Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Other

Global Rare Inflammatory Disease Treatment Market – By Drug Class

  • Biologics
  • Organic Compounds

Global Rare Inflammatory Disease Treatment Market – By Mode of Administration

  • Injectables
  • Oral
  • Others

Global Rare Inflammatory Disease Treatment Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

Global Rare Inflammatory Disease Treatment Market – By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Rare Inflammatory Disease Treatment Market
2.2. Global Rare Inflammatory Disease Treatment Market, By Indication
2.3. Global Rare Inflammatory Disease Treatment Market, By Drug Class
2.4. Global Rare Inflammatory Disease Treatment Market, By Mode of Administration
2.5. Global Rare Inflammatory Disease Treatment Market, By Distribution Channel
2.6. Global Rare Inflammatory Disease Treatment Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Rare Inflammatory Disease Treatment Market Value, 2017-2030, (US$ Mn))
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. Drug Class
3.5.3. Mode of Administration
3.5.4. Distribution Channel
3.5.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Indication Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. InDirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Rare Inflammatory Disease Treatment Market
7.1. Global Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
7.1.1. Overview
7.1.2. Global Rare Inflammatory Disease Treatment Market, By Indication, 2022 vs 2030 (in%)
7.1.3. Global Rare Inflammatory Disease Treatment Market, By Ulcerative Colitis, 2017-2030 (US$ Mn))
7.1.4. Global Rare Inflammatory Disease Treatment Market, By Juvenile Rheumatoid Arthritis, 2017-2030 (US$ Mn))
7.1.5. Global Rare Inflammatory Disease Treatment Market, By Psoriatic Arthritis, 2017-2030 (US$ Mn))
7.1.6. Global Rare Inflammatory Disease Treatment Market, By Others, 2017-2030 (US$ Mn))
7.2. Global Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
7.2.1. Overview
7.2.2. Global Rare Inflammatory Disease Treatment Market, By Drug Class, 2022 vs 2030 (in%)
7.2.3. Global Rare Inflammatory Disease Treatment Market, By Biologics, 2017-2030 (US$ Mn))
7.2.4. Global Rare Inflammatory Disease Treatment Market, By Organic Compounds, 2017-2030 (US$ Mn))
7.3. Global Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
7.3.1. Overview
7.3.2. Global Rare Inflammatory Disease Treatment Market, By Mode of Administration, 2022 vs 2030 (in%)
7.3.3. Global Rare Inflammatory Disease Treatment Market, By Injectables, 2017-2030 (US$ Mn))
7.3.4. Global Rare Inflammatory Disease Treatment Market, By Oral, 2017-2030 (US$ Mn))
7.3.5. Global Rare Inflammatory Disease Treatment Market, By Others, 2017-2030 (US$ Mn))
7.4. Global Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
7.4.1. Overview
7.4.2. Global Rare Inflammatory Disease Treatment Market, By Distribution Channel, 2022 vs 2030 (in%)
7.4.3. Global Rare Inflammatory Disease Treatment Market, By Hospital Pharmacies, 2017-2030 (US$ Mn))
7.4.4. Global Rare Inflammatory Disease Treatment Market, By Retail Pharmacies, 2017-2030 (US$ Mn))

8. North America Rare Inflammatory Disease Treatment Market Analysis
8.1. North America Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030(US$ Mn))
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030(US$ Mn))
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030(US$ Mn))
8.3.1. Overview
8.3.2. SRC Analysis
8.4. North America Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
8.4.1. Overview
8.4.2. SRC Analysis
8.5. North America Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
8.5.1. U.S.
8.5.1.1. U.S. Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.5.1.2. U.S. Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
8.5.1.3. U.S. Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
8.5.1.4. U.S. Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
8.5.1.5. U.S. Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
8.5.2. Canada
8.5.2.1. Canada Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.5.2.2. Canada Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
8.5.2.3. Canada Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
8.5.2.4. Canada Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
8.5.2.5. Canada Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

9. Europe Rare Inflammatory Disease Treatment Market Analysis
9.1. Europe Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030(US$ Mn))
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030(US$ Mn))
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030(US$ Mn))
9.3.1. Overview
9.3.2. SRC Analysis
9.4. Europe Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
9.4.1. Overview
9.4.2. SRC Analysis
9.5. Europe Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
9.5.1. Germany
9.5.1.1. Germany Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.1.2. Germany Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.1.3. Germany Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.1.4. Germany Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.1.5. Germany Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.2. France
9.5.2.1. France Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.2.2. France Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.2.3. France Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.2.4. France Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.2.5. France Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.3. UK
9.5.3.1. UK Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.3.2. UK Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.3.3. UK Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.3.4. UK Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.3.5. UK Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.4. Italy
9.5.4.1. Italy Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.4.2. Italy Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.4.3. Italy Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.4.4. Italy Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.4.5. Italy Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.5. Spain
9.5.5.1. Spain Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.5.2. Spain Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.5.3. Spain Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.5.4. Spain Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.5.5. Spain Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
9.5.6. Rest of Europe
9.5.6.1. Rest of Europe Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.5.6.2. Rest of Europe Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
9.5.6.3. Rest of Europe Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
9.5.6.4. Rest of Europe Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
9.5.6.5. Rest of Europe Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

10. Asia Pacific Rare Inflammatory Disease Treatment Market Analysis
10.1. Asia Pacific Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030(US$ Mn))
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030(US$ Mn))
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030(US$ Mn))
10.3.1. Overview
10.3.2. SRC Analysis
10.4. Asia Pacific Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
10.4.1. Overview
10.4.2. SRC Analysis
10.5. Asia Pacific Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
10.5.1. China
10.5.1.1. China Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.1.2. China Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.1.3. China Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.1.4. China Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.1.5. China Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.2. Japan
10.5.2.1. Japan Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.2.2. Japan Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.2.3. Japan Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.2.4. Japan Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.2.5. Japan Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.3. India
10.5.3.1. India Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.3.2. India Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.3.3. India Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.3.4. India Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.3.5. India Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.4. South Korea
10.5.4.1. South Korea Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.4.2. South Korea Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.4.3. South Korea Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.4.4. South Korea Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.4.5. South Korea Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.5. South-East Asia
10.5.5.1. South-East Asia Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.5.2. South-East Asia Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.5.3. South-East Asia Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.5.4. South-East Asia Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.5.5. South-East Asia Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
10.5.6. Rest of Asia Pacific
10.5.6.1. Rest of Asia Pacific Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.5.6.2. Rest of Asia Pacific Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
10.5.6.3. Rest of Asia Pacific Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
10.5.6.4. Rest of Asia Pacific Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
10.5.6.5. Rest of Asia Pacific Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

11. Latin America Rare Inflammatory Disease Treatment Market Analysis
11.1. Latin America Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030(US$ Mn))
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030(US$ Mn))
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030(US$ Mn))
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
11.4.1. Overview
11.4.2. SRC Analysis
11.5. Latin America Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
11.5.1. Brazil
11.5.1.1. Brazil Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.1.2. Brazil Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
11.5.1.3. Brazil Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
11.5.1.4. Brazil Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
11.5.1.5. Brazil Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
11.5.2. Mexico
11.5.2.1. Mexico Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.2.2. Mexico Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
11.5.2.3. Mexico Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
11.5.2.4. Mexico Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
11.5.2.5. Mexico Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
11.5.3. Rest of Latin America
11.5.3.1. Rest of Latin America Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.5.3.2. Rest of Latin America Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
11.5.3.3. Rest of Latin America Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
11.5.3.4. Rest of Latin America Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
11.5.3.5. Rest of Latin America Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

12. Middle East and Africa Rare Inflammatory Disease Treatment Market Analysis
12.1. Middle East and Africa Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030(US$ Mn))
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030(US$ Mn))
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030(US$ Mn))
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030(US$ Mn))
12.4.1. Overview
12.4.2. SRC Analysis
12.5. Middle East and Africa Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
12.5.1. GCC Countries
12.5.1.1. GCC Countries Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.1.2. GCC Countries Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
12.5.1.3. GCC Countries Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
12.5.1.4. GCC Countries Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
12.5.1.5. GCC Countries Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
12.5.2. South Africa
12.5.2.1. South Africa Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.2.2. South Africa Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
12.5.2.3. South Africa Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
12.5.2.4. South Africa Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
12.5.2.5. South Africa Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))
12.5.3. Rest of Middle East and Africa
12.5.3.1. Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.5.3.2. Rest of Middle East and Africa Rare Inflammatory Disease Treatment, By Indication, 2017-2030 (US$ Mn))
12.5.3.3. Rest of Middle East and Africa Rare Inflammatory Disease Treatment, By Drug Class, 2017-2030 (US$ Mn))
12.5.3.4. Rest of Middle East and Africa Rare Inflammatory Disease Treatment, By Mode of Administration, 2017-2030 (US$ Mn))
12.5.3.5. Rest of Middle East and Africa Rare Inflammatory Disease Treatment, By Distribution Channel, 2017-2030 (US$ Mn))

13. Company Profiles
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Bausch Health Companies Inc
13.3. Novartis AG
13.4. Allergan Plc
13.5. Abbott
13.6. Regeneron Pharmaceuticals, Inc
13.7. Abbvie, Inc
13.8. Mallinckrodt
13.9. Celtaxsys
13.10. CSL

List of Figures

FIG. 1 Global Rare Inflammatory Disease Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Rare Inflammatory Disease Treatment Market Segmentation
FIG. 4 Global Rare Inflammatory Disease Treatment Market, by Indication, 2022 (US$ Mn))
FIG. 5 Global Rare Inflammatory Disease Treatment Market, by Drug Class, 2022 (US$ Mn))
FIG. 6 Global Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2022 (US$ Mn))
FIG. 7 Global Rare Inflammatory Disease Treatment Market, by Geography, 2022 (US$ Mn))
FIG. 8 Attractive Investment Proposition, by Indication, 2022
FIG. 9 Attractive Investment Proposition, by Drug Class, 2022
FIG. 10 Attractive Investment Proposition, by Distribution Channel, 2022
FIG. 11 Attractive Investment Proposition, by Geography, 2022
FIG. 12 Global Market Share Analysis of Key Rare Inflammatory Disease Treatment Market Manufacturers, 2022
FIG. 13 Global Market Positioning of Key Rare Inflammatory Disease Treatment Market Manufacturers, 2022
FIG. 14 Global Rare Inflammatory Disease Treatment Market Value Contribution, By Indication, 2022 & 2030 (Value %)
FIG. 15 Global Rare Inflammatory Disease Treatment Market, by Ulcerative Colitis, Value, 2017-2030 (US$ Mn))
FIG. 16 Global Rare Inflammatory Disease Treatment Market, by Juvenile Rheumatoid Arthritis, Value, 2017-2030 (US$ Mn))
FIG. 17 Global Rare Inflammatory Disease Treatment Market, by Psoriatic Arthritis, Value, 2017-2030 (US$ Mn))
FIG. 18 Global Rare Inflammatory Disease Treatment Market, by Others, Value, 2017-2030 (US$ Mn))
FIG. 19 Global Rare Inflammatory Disease Treatment Market Value Contribution, By Drug Class, 2022 & 2030 (Value %)
FIG. 20 Global Rare Inflammatory Disease Treatment Market, by Biologics, Value, 2017-2030 (US$ Mn))
FIG. 21 Global Rare Inflammatory Disease Treatment Market, by Organic Compounds, 2017-2030 (US$ Mn))
FIG. 22 Global Rare Inflammatory Disease Treatment Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)
FIG. 23 Global Rare Inflammatory Disease Treatment Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Mn))
FIG. 24 Global Rare Inflammatory Disease Treatment Market, by Retail Pharmacies, 2017-2030 (US$ Mn))
FIG. 25 North America Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 26 U.S. Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 27 Canada Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 28 Europe Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 29 Germany Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 30 France Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 31 U.K. Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 32 Italy Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 33 Spain Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 34 Rest of Europe Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 35 Asia Pacific Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 36 China Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 37 Japan Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 38 India Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 39 South Korea Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 40 South-East Asia Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 41 Rest of Asia Pacific Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 42 Latin America Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 43 Brazil Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 44 Mexico Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 45 Rest of Latin America Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 46 Middle East & Africa Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 47 GCC Countries Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 48 South Africa Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))
FIG. 49 Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market, 2017-2030 (US$ Mn))

List of Tables

TABLE 1 Market Snapshot: Global Rare Inflammatory Disease Treatment Market
TABLE 2 Global Rare Inflammatory Disease Treatment Market, by Competitive Benchmarking, 2022
TABLE 3 Global Rare Inflammatory Disease Treatment Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Rare Inflammatory Disease Treatment Market, by Key Strategies Analysis, 2022
TABLE 5 Global Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 6 Global Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 7 Global Rare Inflammatory Disease Treatment Market, by Mode of Administration,, 2017-2030 (US$ Mn))
TABLE 8 Global Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 9 Global Rare Inflammatory Disease Treatment Market, by Geography, 2017-2030 (US$ Mn))
TABLE 10 North America Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 11 North America Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 12 North America Rare Inflammatory Disease Treatment Market, by Mode of Administration,, 2017-2030 (US$ Mn))
TABLE 13 North America Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 14 North America Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 15 US Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 16 US Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 17 US Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 18 US Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 19 Canada Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 20 Canada Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 21 Canada Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 22 Canada Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 23 Europe Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 24 Europe Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 25 Europe Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 26 Europe Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 27 Europe Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 28 Germany Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 29 Germany Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 30 Germany Rare Inflammatory Disease Treatment Market, by Mode of Administration,, 2017-2030 (US$ Mn))
TABLE 31 Germany Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 32 France Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 33 France Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 34 France Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 35 France Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 36 UK Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 37 UK Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 38 UK Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 39 UK Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 40 Italy Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 41 Italy Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 42 Italy Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 43 Italy Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 44 Spain Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 45 Spain Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 46 Spain Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 47 Spain Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 48 Rest of Europe Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 49 Rest of Europe Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 50 Rest of Europe Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 51 Rest of Europe Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 52 Asia Pacific Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 53 Asia Pacific Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 54 Asia Pacific Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 55 Asia Pacific Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 56 Asia Pacific Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 57 China Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 58 China Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 59 China Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 60 China Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 61 Japan Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 62 Japan Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 63 Japan Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 64 Japan Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 65 India Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 66 India Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 67 India Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 68 India Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 69 South Korea Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 70 South Korea Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 71 South Korea Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 72 South Korea Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 73 South-East Asia Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 74 South-East Asia Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 75 South-East Asia Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 76 South-East Asia Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 77 Rest of Asia Pacific Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 78 Rest of Asia Pacific Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 79 Rest of Asia Pacific Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 80 Rest of Asia Pacific Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 81 Latin America Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 82 Latin America Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 83 Latin America Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 84 Latin America Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 85 Latin America Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 86 Brazil Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 87 Brazil Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 88 Brazil Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 89 Brazil Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 90 Mexico Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 91 Mexico Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 92 Mexico Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 93 Mexico Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 94 Rest of Latin America Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 95 Rest of Latin America Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 96 Rest of Latin America Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 97 Rest of Latin America Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 98 Middle East and Africa Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 99 Middle East and Africa Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 100 Middle East and Africa Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 101 Middle East and Africa Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 102 Middle East and Africa Rare Inflammatory Disease Treatment Market, by Country, 2017-2030 (US$ Mn))
TABLE 103 GCC Countries Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 104 GCC Countries Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 105 GCC Countries Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 106 GCC Countries Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 107 South Africa Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 108 South Africa Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 109 South Africa Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 110 South Africa Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))
TABLE 111 Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market, by Indication, 2017-2030 (US$ Mn))
TABLE 112 Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market, by Drug Class, 2017-2030 (US$ Mn))
TABLE 113 Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market, by Mode of Administration, 2017-2030 (US$ Mn))
TABLE 114 Rest of Middle East and Africa Rare Inflammatory Disease Treatment Market, by Distribution Channel, 2017-2030 (US$ Mn))

Frequently Asked Questions

How does COVID-19 Impact the global Rare Inflammatory Disease Treatment market?

Healthcare professionals heavily used anti-inflammatory medications during the height of the pandemic crisis to relieve complications suffered by severely ill and immunocompromised patients.

Which is the leading region of the market for Rare Inflammatory Disease Treatment?

North America accounted for the most heightened share in the global Rare Inflammatory Disease Treatment market.

What are the key drivers for the growth of the Rare Inflammatory Disease Treatment market?

The market demand for rare inflammatory disease treatments has been further boosted by rising R&D expenditures for various drug developments and demand for various drug administration methods.

Which is the major segment in the Rare Inflammatory Disease Treatment market by type?

The biologics segment had a major share in the global market in 2022.

Which is the major segment in the Rare Inflammatory Disease Treatment market by application?

The hospital pharmacy segment had a major share in the global market.

Download Sample Report

Have a question?

Market Research Analyst

Don’t settle for less – trust Ishika to help you find the best solution.

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 8085 89 5002


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN